WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development

February 8, 2018

Responsive image

SHANGHAI, Feb. 8, 2018 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today congratulated its partner Tychan for dosing the first patient…

Category: Precious Metals